Table 2 Treatment outcomes on day 28, according to study cohort (AL or ASAQ) at various sites in Mozambique
Study site | ||||||
|---|---|---|---|---|---|---|
Cohort 1: Artemether-Lumefantrine | Montepuez | Dondo | Chokwe | Manhiça | Tete | TOTAL |
Variable | N = 88 | N = 88 | N = 86 | N = 89 | N = 88 | N = 439 |
ACPRa (uncorrected) n | 65 | 70 | 70 | 62 | 68 | 335 |
ETFb n | 0 | 0 | 1 | 0 | 0 | 1 |
LCFc n | 4 | 4 | 0 | 0 | 0 | 8 |
LPFd n | 9 | 6 | 6 | 5 | 4 | 30 |
New infections (with PCR) n | 9 | 7 | 4 | 3 | 2 | 25 |
Recrudescences (with PCR) n | 4 | 3 | 2 | 2 | 2 | 13 |
No treatment outcome (loss to follow-up or withdrawn) n | 10 | 8 | 9 | 22 | 16 | 66 |
PPe day-28 efficacy (PCR-uncorrected) n/N (95%CI) | 65/78 (83.3) [73.2-90.8] | 70/80 (87.5) [78.2-93.8] | 70/77 (90.9) [82.2-96.3] | 62/67 (92.5) [83.4-97.5] | 68/72 (94.4) [86.4-98.5] | 335/374 (89.6) [86.0-92.5] |
PP day-28 efficacy (PCR-corrected) n/N (95%CI) | 65/69 (94.2) [85.8-98.4] | 70/73 (95.9) [88.5-99.1] | 70/73 (95.9) [88.5-99.1] | 62/64 (96.9) [89.2-99.6] | 68/70 (97.) [90.1-99.7] | 335/349 (96.0) [93.4-97.8] |
Cohort 2: Artesunate-amodiaquine | Montepuez | Dondo | Chokwe | Manhiça | Tete | TOTAL |
Variable | N = 87 | N = 87 | N = 87 | N = 0 | N = 0 | N = 261 |
ACPRa (uncorrected) n | 81 | 78 | 73 | NA | NA | 232 |
ETFb n | 0 | 0 | 0 | NA | NA | 0 |
LCFc n | 0 | 0 | 0 | NA | NA | 0 |
LPFd n | 0 | 0 | 1 | NA | NA | 1 |
New infections (with PCR) n | 0 | 0 | 0 | NA | NA | 0 |
Recrudescences (with PCR) n | 0 | 0 | 1 | NA | NA | 1 |
No treatment outcome (loss to follow up or withdrawn) n | 6 | 9 | 13 | NA | NA | 28 |
PP day-28 efficacy (PCR-uncorrected) n/N (95%CI) | 81/81 (100) [NA] | 78/78 (100) [NA] | 73/74 (98.6) [92.7-99.9] | NA | NA | 232/233 (99.6) [97.6-99.9] |
PP day-28 efficacy (PCR-corrected) n/N (95%CI) | 81/81 (100) [NA] | 78/78 (100) [NA] | 73/74 (98.6) [92.7-99.9] | NA | NA | 232/233 (99.6) [97.6-99.9] |